Mersana Therapeutics (STU:0M4) Short Percentage of Float

View and export this data going back to 2019. Start your Free Trial

What is Mersana Therapeutics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Mersana Therapeutics's Short Percentage of Float

For the Biotechnology subindustry, Mersana Therapeutics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mersana Therapeutics's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mersana Therapeutics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Mersana Therapeutics's Short Percentage of Float falls into.

Mersana Therapeutics (STU:0M4) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mersana Therapeutics Inc (STU:0M4) » Definitions » Short Percentage of Float

Comparable Companies

Traded in Other Exchanges

MRSN:USA 0M4:Germany

Address

840 Memorial Drive, Cambridge, MA, USA, 02139

Website

https://www.mersana.com

Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.

Mersana Therapeutics (STU:0M4) Headlines

No Headlines